Journal of gastrointestinal cancer · 2026
Viral vs. Non-Viral Combined Hepatocellular-Cholangiocarcinoma: Distinct Genomic Landscapes and Survival Outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Puttagunta Neha, Friedman Matthew, Khandakar Binny, Brown Timothy J, Grewal Udhayvir Singh, Hornstein Nicholas
Аннотация
PURPOSE: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare, biologically heterogeneous primary liver cancer with conflicting reported outcomes. The prognostic impact of viral hepatitis in cHCC-CCA remains unclear. Given its established influence in hepatocellular carcinoma, we evaluated whether viral etiology is associated with distinct clinical and genomic features in cHCC-CCA.
METHODS: A structured PubMed and Embase search identified case reports and series describing viral status, treatment, and overall survival (OS) in cHCC-CCA. Studies lacking OS attribution or viral status were excluded. Due to heterogeneous follow-up and absence of standardized censoring, survival was analyzed descriptively, with viral versus non-viral OS compared using Mann-Whitney U testing. A complementary genomic cohort from cBioPortal was analyzed to compare mutation frequencies between viral and non-viral cases.
RESULTS: Median OS was 49.5 months for viral versus 20.0 months for non-viral disease (mean 47.7 ± 18.5 vs 29.6 ± 16.2 months; p = 0.023). A crude hazard approximation suggested lower mortality risk in viral cases (HR ≈ 0.40), though formal time-to-event analysis was not feasible. In the genomic cohort, viral cases similarly demonstrated longer mean OS (23.1 vs 13.0 months; p < 0.05). Non-viral tumors showed enrichment of mutations including IDH, SLC16A1, CLDN18, HMCN1, ADAMTS8, BNC1, YES1, and TGFBR1.
CONCLUSION: Viral cHCC-CCA was associated with longer observed survival across clinical and genomic datasets. Non-viral tumors demonstrated enrichment of mutations associated with metabolic reprogramming, proliferative signaling, pathway escape, and metastatic biology, potentially contributing to poorer outcomes. These hypothesis-generating findings require validation in prospective cohorts with standardized genomic annotation.
METHODS: A structured PubMed and Embase search identified case reports and series describing viral status, treatment, and overall survival (OS) in cHCC-CCA. Studies lacking OS attribution or viral status were excluded. Due to heterogeneous follow-up and absence of standardized censoring, survival was analyzed descriptively, with viral versus non-viral OS compared using Mann-Whitney U testing. A complementary genomic cohort from cBioPortal was analyzed to compare mutation frequencies between viral and non-viral cases.
RESULTS: Median OS was 49.5 months for viral versus 20.0 months for non-viral disease (mean 47.7 ± 18.5 vs 29.6 ± 16.2 months; p = 0.023). A crude hazard approximation suggested lower mortality risk in viral cases (HR ≈ 0.40), though formal time-to-event analysis was not feasible. In the genomic cohort, viral cases similarly demonstrated longer mean OS (23.1 vs 13.0 months; p < 0.05). Non-viral tumors showed enrichment of mutations including IDH, SLC16A1, CLDN18, HMCN1, ADAMTS8, BNC1, YES1, and TGFBR1.
CONCLUSION: Viral cHCC-CCA was associated with longer observed survival across clinical and genomic datasets. Non-viral tumors demonstrated enrichment of mutations associated with metabolic reprogramming, proliferative signaling, pathway escape, and metastatic biology, potentially contributing to poorer outcomes. These hypothesis-generating findings require validation in prospective cohorts with standardized genomic annotation.